Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer: The Cancer Research Network, Inc., experience

Alejandra Perez, Gabriel H. Domenech, Cynthia Frankel, Charles Vogel

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.

Original languageEnglish
Pages (from-to)22-29
Number of pages8
JournalCancer Investigation
Volume20
Issue numberSUPPL. 2
StatePublished - Nov 21 2002
Externally publishedYes

Fingerprint

Breast Neoplasms
Research
Mucositis
Neoplasms
Safety
Private Practice
Leukopenia
Doxorubicin
Appointments and Schedules
liposomal doxorubicin

Keywords

  • Anthracycline
  • Chemotherapy
  • Doxorubicin
  • Drug delivery
  • Liposome
  • Metastatic breast cancer
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer : The Cancer Research Network, Inc., experience. / Perez, Alejandra; Domenech, Gabriel H.; Frankel, Cynthia; Vogel, Charles.

In: Cancer Investigation, Vol. 20, No. SUPPL. 2, 21.11.2002, p. 22-29.

Research output: Contribution to journalArticle

@article{c30b148819f54fbf814ea44db3eb04d9,
title = "Pegylated liposomal doxorubicin (Doxil{\circledR}) for metastatic breast cancer: The Cancer Research Network, Inc., experience",
abstract = "Pegylated liposomal doxorubicin (Doxil{\circledR}) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43{\%} in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18{\%})patients, mucositis in one (3{\%}), and palmar-plantar erythrodysesthesia in one (3{\%}). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.",
keywords = "Anthracycline, Chemotherapy, Doxorubicin, Drug delivery, Liposome, Metastatic breast cancer, Pegylated liposomal doxorubicin",
author = "Alejandra Perez and Domenech, {Gabriel H.} and Cynthia Frankel and Charles Vogel",
year = "2002",
month = "11",
day = "21",
language = "English",
volume = "20",
pages = "22--29",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer

T2 - The Cancer Research Network, Inc., experience

AU - Perez, Alejandra

AU - Domenech, Gabriel H.

AU - Frankel, Cynthia

AU - Vogel, Charles

PY - 2002/11/21

Y1 - 2002/11/21

N2 - Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.

AB - Pegylated liposomal doxorubicin (Doxil®) was formulated to improve the safety profile of doxorubicin. The major toxicities, mucositis and palmar-plantar erythrodysesthesia, are dose and schedule dependent, respectively. Anecdotal experience suggests that a dosage of 40 mg/m2 every 4 weeks is well tolerated. To evaluate the safety and efficacy of this regimen in women with metastatic breast cancer, we performed a retrospective chart review at a private practice. Forty women received a median initial dose of 42.5 mg/m2 usually every 4 weeks and a median cumulative dose of 135 mg/m2 (range: 40-595 mg/m2). There were 10 partial responses and seven patients with stable disease for more than 6 months resulting in a clinical benefit rate of 43% in the intent-to-treat analysis. The median time to progression was 4 months in all patients, 6.5 months in patients who had partial responses, and 10 months in patients who had stable disease for more than 6 months. There was no grade 4 toxicity. The only grade 3 toxicities were leukopenia in seven (18%)patients, mucositis in one (3%), and palmar-plantar erythrodysesthesia in one (3%). More studies are warranted to confirm our findings, which suggest that pegylated liposomal doxorubicin at a dosage of 40-45 mg/m2 every 4 weeks is clinically active in, and well tolerated by, women with metastatic breast cancer.

KW - Anthracycline

KW - Chemotherapy

KW - Doxorubicin

KW - Drug delivery

KW - Liposome

KW - Metastatic breast cancer

KW - Pegylated liposomal doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0036420885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036420885&partnerID=8YFLogxK

M3 - Article

C2 - 12442346

AN - SCOPUS:0036420885

VL - 20

SP - 22

EP - 29

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - SUPPL. 2

ER -